Myrtus communis effect in acne treatment

Not Applicable

Conditions: Acne vulgaris.
Acne vulgaris
L70.0

Registration Number: IRCT20171122037581N1

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 55

Inclusion Criteria

Being 12–45 years old
Facial acne vulgaris, mild to moderate ( Having 20-140 total lesion count, 10-90 noninflammatory facial lesions, 10-50 inflammatory lesions, without facial nodular cystic lesion)

Exclusion Criteria

Have a skin disease that might interfere with the diagnosis or evaluation of their skin lesions
Severe systemic disease
Pregnant and lactating women
Use of topical anti acne therapy two months before or during the study
Use of oral retinoids six months before the study
known allergy or sensitivity to any of the study medications or their components
Incidence of side effects
Unwillingness to continue this study
Unable to follow up the patient regularly

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total lesion Count. Timepoint: At the beginning of the study and at the end of the sixth, twelfth and sixteenth week of the study. Method of measurement: Counting the Comedones, Papules and Pustules.;Severity of Acne. Timepoint: At the beginning of the study and at the end of the sixth, twelfth and sixteenth week of the study. Method of measurement: Acne Severity Index.;Speed of onset of treatment(The mean time to a 50% reduction in acne lesion ) in every half of the face. Timepoint: At the end of the sixth and twelfth week. Method of measurement: Index of Severity of Acne=ASI Total lesion Count = TLC.;Recurrence. Timepoint: 4 weeks after treatment. Method of measurement: Index of Severity of Acne=ASI Total lesion Count = TLC.

Secondary Outcome Measures